ars-pharma.comHealthcareFounded: 2015Funding to Date: $76.55MM
ARS pharmaceuticals is developing an intranasal epinephrine spray for patients at-risk of severe allergic reactions to food, medications and insect bites that could lead to anaphylaxis.
View Enterprise Value for ARS Pharmaceuticals.
